Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Insmed (Nasdaq: INSM) has announced its management team will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Monday, January 13, 2025, at 3:00 p.m. PT/6:00 p.m. ET.

The event will be accessible via webcast through the investor relations section of Insmed's website at www.insmed.com. The webcast recording will remain available for 30 days after the live presentation concludes.

News Market Reaction – INSM

+1.32%

+1.32% Session move

In the trading session that priced this news, INSM gained 1.32%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 3:00 p.m. PT/6:00 p.m. ET.

This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com

Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com

Gianna De Palma
Manager, Investor Relations
(973) 886-2236
gianna.depalma@insmed.com

Media:

Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302337799.html

SOURCE Insmed Incorporated

FAQ

When is Insmed (INSM) presenting at the 2025 J.P. Morgan Healthcare Conference?

Insmed is scheduled to present on Monday, January 13, 2025, at 3:00 p.m. PT/6:00 p.m. ET.

How can investors watch Insmed's (INSM) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via webcast through the investor relations section of Insmed's website at www.insmed.com.

How long will Insmed's (INSM) J.P. Morgan Healthcare Conference presentation be available online?

The webcast will be archived and available for 30 days following the conclusion of the live event.

Which annual J.P. Morgan Healthcare Conference is Insmed (INSM) participating in?

Insmed is participating in the 43rd Annual J.P. Morgan Healthcare Conference.